The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance study on Oral Contraceptives based on 142,475 women-years of observation
Top Cited Papers
- 31 May 2007
- journal article
- research article
- Published by Elsevier BV in Contraception
- Vol. 75 (5), 344-354
- https://doi.org/10.1016/j.contraception.2006.12.019
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimensClimacteric, 2004
- Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosisClimacteric, 2004
- Additive effect of drospirenone/17-β-estradiol in hypertensive postmenopausal women receiving enalapril1American Journal of Hypertension, 2002
- Case-control studies on venous thromboembolism: bias due to design? A methodological study on venous thromboembolism and steroid hormone useContraception, 2002
- Third generation oral contraceptives and risk of venous thrombosis: meta-analysisBMJ, 2001
- Drospirenone: pharmacology and pharmacokinetics of a unique progestogenContraception, 2000
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995